Trial reportAddictive behaviors2023
Cannabis use for medical symptoms: Patterns over the first year of use.
Trial report in Addictive behaviors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03224468 (Effect of Medical Marijuana on Neurocognition and Escalation of Use), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Medical Marijuana on Neurocognition and Escalation of Use
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Factors associated with cannabis use disorder among Australians using prescribed and illicitly-sourced medical cannabis.Drug and alcohol dependence reports · 2025Article
- Effects of Cannabis Use for Medical Symptoms on Cannabis Use Disorder Symptoms: A 24-Month Follow-up Study.American journal of preventive medicine · 2025Article
- The prevalence and correlates of self-reported cannabis use for medicinal, dual and recreational motives in Australia: Findings from the National Drug Strategy Household Survey 2022/2023.Drug and alcohol review · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAs greater numbers of states in the United States and countries in the world continue to legalize cannabis for medical use, it has become increasingly important to assess patterns of cannabis use in individuals using cannabis for medical symptoms over time. A public health concern is that, like recreational cannabis, some individuals using cannabis for medical reasons may develop detrimental patterns of use, leading to the development of a cannabis use disorder (CUD).
methodsIn a 9-month longitudinal cohort study following a 12-week randomized, waitlist-controlled trial in 149 adults who used cannabis to alleviate insomnia, pain, depressed mood, or anxiety (RCT: NCT03224468), we assessed whether patterns of cannabis use for the 9 months following the RCT were associated with the development of CUD.
resultsWe identified five unique trajectories of use; 31 participants (21%) had low stable or no use, 50 (34%) had medium stable use, 19 (13%) had high stable use, 26 (17%) showed de-escalating and 23 (15%) showed escalating use over 9 months following the RCT. Of 149 participants enrolled, 19 (13%) met diagnostic criteria for CUD at 12 months. Only the escalating cannabis use pattern predicted significantly higher rates of CUD compared to the low or no use category (OR = 4.29, 95% CI = 1.21 to 10.87, p = 0.02).
conclusionsThese data indicate that most individuals using cannabis for medical symptoms have a stable pattern of use over the first year. Escalation of use may be a detrimental pattern that warrants further concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.